Search Results - clinical+and+disease+specializations+%3e+oncology+%3e+glioma

5 Results

Sort By:

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 3/13/2025 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases

Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...

Published: 3/13/2025 | Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Polymer-based Acriflavine Wafers for the Treatment of Malignant Brain Cancer

Value Proposition:· Intracranial wafers deliver anti-cancer drugs directly to the tumor, circumventing pharmacokinetic barriers.· Repurposes acriflavine and polymers, both with other FDA approvals, for malignant glioma.· High-efficacy treatment option to prolong survival for the most common form of aggressive brain cancer.· 10-fold...

Published: 3/13/2025 | Inventor(s): Betty Tyler, Antonella Mangraviti, Henry Brem, Alessandro Olivi, Tula Raghavan

Keywords(s): Brain Cancer, Cancers, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Glioma, Non-novel, Polymers, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

IDH1 Mutant Glioma Xenograft (JHH-273)

Invention Novelty: A stable, patient-derived IDH- 1 mutant glioma xenograft designed to evaluate potential IDH targeted drug therapies.Value Proposition: IDH-1 (Isocitrate Dehydrogenase) is a very common mutation observed in low-grade glioma tumors. Current IDH-mutated cell lines lack sufficient genetic characteristics similar to human pathologies and...

Published: 3/13/2025 | Inventor(s): Alexandra Borodovsky, Gregory Riggins

Keywords(s): Basic Research Biomarker, Brain Cancer, Cancers, Discovery/Research Tools, Disease Indication, Glioma, In Vivo Research Tool, Mouse Model, Mouse Model Xenograft

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma, Technology Classifications > Research Tools > Animal Models, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Glioblastoma Biomarker for Improved Survival Prediction

TITLE: Glioblastoma Biomarker for Improved Survival PredictionCASE NUMBER: C13155UNMET NEEDGlioblastoma GBM), the most common primary brain tumor, has few available therapies providing significant improvement in survival. The median survival of patients after treatment is ~15 months, with only 3-5% surviving longer than 3 years. However, survival varies...

Published: 3/13/2025 | Inventor(s): Patrick Ha, Michael Lim, Chetan Bettegowda, Taeyoung Hwang, Chul-Kee Park, Dimitrios Mathios

Keywords(s): Biomarker, Brain Cancer, Breast Cancer, Cancers, Cervical Cancer, Clinical Diagnostics, Disease Indication, Glioma, In Vitro Diagnostics, Lung Cancer, Prognostic Biomarker